Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Hans-Ludwig Schäfer

Heiner Glombik

Wendelin Frick

Gerhard Jaehne

Hubert Heuer

Stefanie Flohr

Andreas Lindenschmidt

Werner Krame

Werner Kramer

Stefanie Keil

Wolfgang Wendler

Lothar Schwink

Eugen Falk

Reinhard Kirsch

Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use

Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals

Compounds of the formula I,in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described. Also described are compounds of formula Iin which the radicals have the abovementioned meanings, and their physiologically tolerated salts, physiologically functional derivates and processes for their preparation. The compounds are suitable as, for example, hypolipidemics.

Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives

Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I,in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

Growing community of inventors

Hochheim, Germany

Hans-Ludwig Schäfer